Concomitant endometrial hyperplasia in patients with endometrial carcinoma

Gynecol Oncol. 1998 Apr;69(1):64-8. doi: 10.1006/gyno.1997.4911.

Abstract

Objectives: The aim of this study was to compare the histopathologic features and prognosis of patients with endometrial carcinoma with and without concomitant hyperplasia.

Methods: Histologic slides of the surgical specimens of 214 consecutive patients who underwent surgery as primary treatment for endometrial carcinoma from 1985 through 1991 were reviewed.

Results: Ninety-two of the 214 patients (43%) with endometrial carcinoma had concomitant endometrial hyperplasia. Patients with endometrial carcinoma with hyperplasia were significantly younger than those without hyperplasia (mean age 62 +/- 10 vs 65 +/- 9 years, P < 0.05). Carcinomas associated with hyperplasia were better differentiated and of lower surgical stage. By univariate analysis the frequency of recurrence was significantly lower (4% vs 17%, P < 0.004) and the estimated 5-year survival rate significantly higher (96% vs 85%, P < 0.01) in patients with endometrial carcinoma with concomitant hyperplasia. However, in multivariate analysis the presence of endometrial hyperplasia was not an independent prognostic factor and the 5-year survival rates of patients with or without hyperplasia did not differ significantly in any surgical stage.

Conclusion: The presence or absence of concomitant endometrial hyperplasia is strongly correlated with the surgical stage of endometrial carcinoma.

MeSH terms

  • Adenocarcinoma / pathology
  • Adenocarcinoma, Clear Cell / pathology
  • Age Factors
  • Aged
  • Carcinoma, Adenosquamous / pathology
  • Cystadenocarcinoma, Papillary / pathology
  • Endometrial Hyperplasia / pathology*
  • Endometrial Neoplasms / pathology*
  • Female
  • Humans
  • Metaplasia / pathology
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Recurrence
  • Retrospective Studies
  • Survival Analysis